

## PERSONAL INFORMATION

## Marta Brambilla

Sex female | Date of birth 04/05/1989 | Nationality Italian

## POSITION

- 05/11/2020 – today** Medical Oncologist, Department of Medical Oncology  
Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit – Casual labour for "Epithelial thymic tumors network" project.

## WORK EXPERIENCE

- 05/11/2020 – today** Medical Oncologist, Department of Medical Oncology  
Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit
- 01/11/2017 – 04/11/2020** Specialist registrar, Department of Medical Oncology  
Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit, Gastro-Intestinal Cancer Unit, Breast cancer Unit, Melanoma Unit
- 01/11/2015 – 31/10/2017** Specialist registrar, Department of Medical Oncology  
Santa Maria della Misericordia Hospital and University of Perugia, Italy  
Thoracic Cancer Unit, Internal Medicine ward
- 2006 – 2008** Lifeguard in private swimming pool

## EDUCATION AND TRAINING

- 01/11/2017 – 04/11/2020** Specialist registrar, Department of Medical Oncology  
Degree in Medical Oncology (70/70 cum laude)  
Thesis Title: Circulating and tumor associated neutrophil subtypes in hyperprogressive disease upon immune checkpoint inhibitors in advanced non-small cell lung cancer patients.  
Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit, Gastro-Intestinal Cancer Unit, Breast cancer Unit, Melanoma Unit
- 23/03/2019-28/03/2019** 18<sup>th</sup> ESO-ESMO Masterclass in Oncologia Clinica  
Nauen OT Gross Berhnitz
- 01/11/2015 – 31/10/2017** Specialist registrar, Department of Medical Oncology  
Santa Maria della Misericordia Hospital and University of Perugia, Italy  
Thoracic Cancer Unit, Internal Medicine ward
- 22/07/2015** Member of Italian Medical Association  
Ordine dei medici e degli odontoiatri di Monza e Brianza, n°03967
- September 2008 – March 2015** Bachelor in Medicine and Surgery

### First Class Degree (108/110)

Thesis Title: Phase II clinical trial with Temozolomide in metastatic colorectal cancer selected according to MGMT gene silencing.

University of Milano-Bicocca, Faculty of Medicine and Surgery, Monza, Italy

#### December 2013 – March 2015

##### **Internship in Oncology**

Division of Oncology, Niguarda Ca' Granda Hospital, Milano, Italy

#### October 2012

##### **Internship in Oncology**

Division of Oncology, San Gerardo Hospital, Monza, Italy

#### July 2012

##### **Internship in Clinical Research**

Division of Clinical Research, San Gerardo Hospital, Monza, Italy

#### September 2003– June 2008

##### **Secondary School Diploma**

High School of Science Antonio Banfi, Vimercate, Monza e Brianza, Italy

### SCIENTIFIC AFFILIATIONS

#### August 2019 – today

##### **Member of FONICAP**

ID number 000174

#### November 2017 – today

##### **Member of ESMO**

ID number 409688

#### November 2017 – today

##### **Member of AIOM**

#### 22/07/2015

##### **Member of Italian Medical Association**

Medical Association of Monza and Brianza, ID number 03967

#### 09/07/2015

##### **Board certified in Medicine and Surgery**

### PERSONAL SKILLS

#### Mother tongue(s)

Italian

#### Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2
French	A2	A2	A2	A2	A2

#### Communication skills

Good communication and presentation skills gained through my scholastic experiences.

#### Organizational / managerial skills

Excellent managerial skills gained through my experience of supervisor of Young Component of Red Cross Organization of Monza division.

Excellent organizational skills gained through the activity of planning fund-raising campaign and promoting events as a referent member of Young Component of Red Cross Organization of Monza division.

**Digital competence**

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Independent User	Independent user	Independent user	Independent user	Basic user
Microsoft Windows and Mac OS X Operative Systems. Microsoft Office Suite, in particular Word, Excel and Powerpoint. Good ability using Internet both as a tool of communication and to search scientific information. Use of Medline database, e.g. Pubmed.				

**Driving licence**

B

**SCIENTIFIC INVOLVEMENT**
**Publications**

M. Niger, M. Prisciandaro, M. Antista, M.A.T. Monica, L. Cattaneo, N. Prinzi, S. Manglaviti, F. Nichetti, M. Brambilla, M. Torchio, F. Corti, S. Pusceddu, J. Coppa, V. Mazzaferro, F. de Braud, M. Di Bartolomeo. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. *World J Gastrointest Oncol.* **2020** Aug;12(8):833-849. doi: 10.4251/wjgo.v12.i8.833. PMID: 32879662; PMCID: PMC7443847.

A. Prelaj, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, M. Mensah, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, B. Trevisan, F. Trovò, V. Torri, G. Sozzi, M.C. Garassino, M. Boeri. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. *Transl Lung Cancer Res.* **2020** Jun;9(3):617-628. doi: 10.21037/tlcr-20-231. PMID: 32676324; PMCID: PMC7354114.

F. Corti, M. Brambilla, S. Manglaviti, L. Di Vico, M.N. Pisano, C. Facchinetti, K.F. Dotti, R. Lanocita, A. Marchianò, F. de Braud, L.A.M. Ferrari. Comparison of outcomes of central venous catheters in patients with solid and hematologic neoplasms: an Italian real-world analysis. *Tumori*, **2020** Jun 12:300891620931172. doi: 10.1177/0300891620931172. Epub ahead of print. PMID: 32529962.

G. Galli, A. Trama, L. Abate-Daga, M. Brambilla, M.C. Garassino, A. Fabbri. Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. *Lung Cancer*; May **2020**, Volume 146, August 2020, Pages 66-69

C. Vernieri, M. Prisciandaro, F. Nichetti, R. Lobefaro, G. Peverelli, F. Ligorio, E. Zattarin, M.S. Cona , P. Sepe, F. Corti, S. Manglaviti, M. Brambilla, B. Re, C. Maggi, A. Belfiore, G. Pruner, L. Celio, G. Mariani, G.V. Bianchi, L. Rivoltini, G. Capri, F. de Braud. Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. *Cancers*, Volume 12, Issue 3, March **2020**, Article number 617

A. Prelaj, R. Ferrara, S.E Rebuzzi, C. Proto, D. Signorelli, G. Galli, A. De Toma, G. Randon, F. Pagani, G. Viscardi, M. Brambilla, B. Trevisan, M. Ganzinelli, A. Martinetti, R. Gallucci, R.M. Di Mauro, G. Molino, N. Zilembo, V. Torri, F. de Braud, M.C. Garassino, G. Lo Russo. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer A Validation Cohort. *Cancers*. **2019**, 11, 1954; doi.org/10.3390/cancers11121954

B. Ricciuti, G.C. Leonardi, M. Brambilla. Emerging Biomarkers in the Era of Personalized Cancer Medicine. *Disease Markers*, vol. **2019**, Article ID 5907238, 2 pages, 2019. doi.org/10.1155/2019/5907238.

C. Vernieri, M. Milano, M. Brambilla, A. Mennitto, C. Maggi, M.S. Cona, M. Prisciandaro, C. Fabbroni, L. Celio, G. Mariani, G. Capri, G.V. Bianchi, F. de Braud. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. *Critical Reviews in Oncology/Hematology*. **2019** Jul;139:53-66; doi.org/10.1016/j.critrevonc.2019.05.001

B. Ricciuti, C. Genova, M. Bassanelli, A. De Giglio, M. Brambilla, G. Metro, S. Baglivo, M.G. Dal Bello, A. Ceribelli, F. Grossi, R. Chiari. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. *Clin Lung Cancer.* 2019 May; 20(3):178-185.e2. doi.org/10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27.

C. Vernieri, M. Prisciandaro, M. Brambilla, C. Fabbroni, A. Mennitto, E. Farè, G. Capri, L. Celio, G.V. Bianchi, M. Milano, C. Maggi, M.S. Cona, G. Mariani, S. Cresta, F. De Braud. Single-agent gemcitabine versus carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. *Clin Breast Cancer.* 2019 Apr;19(2):e306-e318; doi.org/10.1016/j.clbc.2018.12.004

B. Ricciuti, C. Genova, A. De Giglio, M. Bassanelli, M.G. Dal Bello, G. Metro, M. Brambilla, S. Baglivo, F. Grossi, R. Chiari. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. *J Cancer Res Clin Oncol.* 2019 Feb;145(2):479-485. doi.org/10.1007/s00432-018-2805-3. Epub 2018 Dec 1.

B. Ricciuti, M. Brambilla, A. Cortellini, A. De Giglio, C. Ficarella, A. Sidoni, G. Bellezza, L. Crinò, V. Ludovini, S. Baglivo, G. Metro, R. Chiari. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. *Clin Transl Oncol.* 2019 Jul; doi.org/10.1007/s12094-019-02175-y

A. De Giglio, R. Porreca, M. Brambilla , G. Metro, E. Prosperi, G. Bellezza, M. Pirro, R. Chiari, B. Ricciuti. Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does Oncogene addiction matter? *Thrombosis Research.* 2018 Mar, 163, 51; doi.org/10.1016/j.thromres.2017.12.004

M. Bassanelli, D. Giannarelli, A.J. Gelibter, F.L. Cerere, R. Chiari, S. Giacinti, S. Scagnoli, M. Milella, B. Ricciuti, M. Roberto, V. Magri, V. Ferraresi, M. Brambilla, P. Marchetti, E. Cortesi, A. Ceribelli. Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC). *Journal of Clinical Oncology.* 2018 36(suppl 5S), abstr 177

B. Ricciuti, G. Metro, M. Brambilla, V. Ludovini, S. Baglivo, A. Siggillino, E. Prosperi, R. Chiari. Acquired resistance to afatinib due to T790M-positive squamous progression in EGFR mutant adenosquamous lung carcinoma. *Journal of Thoracic Oncology.* 2018 Jan, 13(1),e9; doi.org/10.1016/j.jtho.2017.08.025

B. Ricciuti, R. Chiari, F. R. Tofanetti, A. De Giglio, R. Porreca, M. Brambilla, I. Sperduti, G. Bellezza, C. Mencaroni, A. Siggillino, D. Zicari, A. Baldi, V. Ludovini, G. Metro. Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels. *Annals of Oncology.* 2017 Oct, abstr E14

B. Ricciuti, M. Brambilla, G. Metro, S. Baglivo, R. Matocci, M. Pirro, R. Chiari. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. *Med Oncol.* 2017 Jun, 34(6),105.

B. Ricciuti, M. Brambilla, A. De Giglio, G. Metro, R. Porreca, R. Chiari, L. Paglialunga. Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand? *J Radiat Oncol.* 2017 Feb, 6, 11-19. 10.1007/s13566-017-0293-8

G. Metro, B. Ricciuti, M. Brambilla, S. Baglivo, I. Soli, E. Minenza, GC. Leonardi, A. D'arpino, D. Colabrese, M. Tazza, D. Zicari, V. Minotti, R. Chiari. The safety of nivolumab for the treatment of advanced non small cell lung cancer. *Expert Opin Drug Saf.* 2017 Jan;16(1),101; doi.org/10.1080/14740338.2017.1267725

B. Ricciuti, GC. Leonardi, N. Ravaioli, A. De Giglio, M. Brambilla, E. Prosperi, F. Ribacchi, ML. Meacci, L. Crinò, D. Maiettini, R. Chiari, G. Metro. Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. *J Breast Cancer.* 2016 Sep, 19(3), 324; http://dx.doi.org/10.4048/jbc.2016.19.3.324

**Clinical trials**

Sub-investigator: BeTeam: Italian observational study on second line treatment approaches for EGFR-mutated, progressing NSCLC patients in real word clinical practice.

Sub-investigator: BioltaLEE A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole.

Sub-investigator: Tulip: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Sub-investigator: Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status. The Arethusa trial.

Sub-investigator: Phase II Study of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy

Sub-investigator: A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

Sub-investigator: BE-PACIFIC Italian oBsErvational study on Patient mAnagement strategies in real-world Clinical practice For patients with loCally advanced (stage III) NSCLC

*Il sottoscritto MARTA BRAMBILLA, ai sensi di quanto previsto dagli artt. 19, 46 e 47 del D.P.R. 445/2000, consapevole delle conseguenze derivanti in caso di rilascio di dichiarazioni false, dichiara sotto la propria responsabilità che tutte le eventuali fotocopie indicate alla domanda di partecipazione al pubblico concorso, sono conformi all'originale in suo possesso e che ogni dichiarazione resa risponde a verità.*

*In compliance with the GDPR and Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned Decree.*

3/12/2020 /marta brambilla